← Leaderboards
Carl Ola Landgren
Hoag Memorial Hospital Presbyterian
$1,820,254
Attributed
$3,796,086
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,025,797 · 2
CDC$1,492,289 · 2
FDA$278,000 · 1
By mechanism
R01$1,961,946 · 1
U01$1,770,289 · 3
P30$63,851 · 1
Top collaborators
- Gary Allan Ulaner6 shared
- David J Prezant3 shared
- Amit Verma2 shared
- Rachel Zeig-Owens1 shared
Most similar at Hoag Memorial Hospital Presbyterian
Same institution · by research overlap
- Gary Allan Ulaner$1,885,670
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureMultiple MyelomaLaboratoriesTreatment ResponseCombined Modality TherapyInnovationResearch PersonnelMemorial Sloan-Kettering Cancer CenterClinical ApplicationTumorPlasma CellsDesignMonoclonal AntibodiesEarly Phase TrialDosimetryFluorodeoxyglucose Positron Emission TomographyDetectionAntibodiesDetection Of Minimal Residual DiseaseFunding OpportunitiesBone Marrow BiopsyClinically SignificantBurden Of IllnessClinical Trials
Grant awards (18)
Translational and Clinical Oncology Research Program$34,499
P30 · FY2025 · CA · contact PI
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$560,238
R01 · FY2024 · CA
Translational and Clinical Oncology Research Program$29,352
P30 · FY2024 · CA · contact PI
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$577,160
R01 · FY2023 · CA
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$50,000
R01 · FY2023 · CA
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$40,000
R01 · FY2022 · CA
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$598,926
R01 · FY2020 · CA
Myeloma Precursor Disease among WTC responders$492,618
U01 · FY2020 · OH
CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications$135,622
R01 · FY2020 · CA
Early Detection of Hematologic Malignancies in New York City Firefighters Exposed To World Trade Center Dust After The 9/11 Attacks$499,807
U01 · FY2018 · OH
Early Detection of Hematologic Malignancies in New York City Firefighters Exposed To World Trade Center Dust After The 9/11 Attacks$499,864
U01 · FY2017 · OH
Molecular Characterization of Multiple Myeloma Ethnic Disparity$106,000
U01 · FY2016 · FD · contact PI
Molecular Characterization of Multiple Myeloma Ethnic Disparity$172,000
U01 · FY2015 · FD · contact PI
Molecular and clinical profiling$1,125,632
ZIA · FY2011 · CA · contact PI
Population based studies$198,641
ZIA · FY2011 · CA · contact PI
Molecular and clinical profiling$551,509
ZIA · FY2010 · CA · contact PI
Population based studies$97,324
ZIA · FY2010 · CA · contact PI
Population based studies$80,965
ZIA · FY2009 · CA · contact PI